Preliminary Archaeopetrological Study of the Lithic Industry From the l’Hort de la Boquera Rock Shelter (Margalef de Montsant, Tarragona, Spain): Applying Mineralogical and Geochemical Techniques

The l’Hort de la Boquera site is located in the northeastern part of Iberia and its stone tool assemblage includes up to 25,000 flint artefacts. This is the first approach to the analysis of the raw material through an archaeopetrological study. Results were obtained by use of mineralogi¬cal techniques: macroscopic and petrographic analysis, Scanning Electronic Microscopy (SEM), Micro-Raman and X-Ray diffraction (XRD); additionally, Laser Ablation Inductively Coupled Plasma Mass Spectrometry was applied. It has been possible to discriminate at least four flint categories, the ‘Evaporitic flint type’ (with two local subvarieties – ‘Common evaporitic’ and ‘Garnet’ varieties) that comes from local outcrops of the Ulldemolins Complex, and two flint types that had their origin further afield: the ‘Charophyta flint type’ (coming from the Torrente de Cinca Unit) and the ‘Dark flint type’ (from the La Serra Llarga Formation).These results make this study the most comprehensive analysis of raw materials that has been carried out in the area so fa

L'Hort de la Boquera (Margalef de Montsant, Priorat) i el final del Paleolític a la vall mitjana del riu Montsant

L'Hort de la Boquera completa el ric registre de jaciments del final del Paleolític i de l'Epipaleolític a la vall mitjana del riu Montsant. Es presenten les novetats de l'excavació durant els darrers anys: datacions radiomètriques, indústria lítica, dades paleoambientals i manifestacions artístiques i se situen en el context del final del Plistocè i inicis de l'Holocè a les comarques meridionals de Catalunya

Nuevas interpretaciones del Paleolítico Superior Final de la Cataluña meridional: el yacimiento de L'Hort de la Boquera (Priorat, Tarragona)

[eng] This paper publishes for the first time the results of the excavations conducted at L'Hort de la Boquera site (Margalef de Montsant, Tarragona). This site is included in the research project we began in 1979 on the prehistoric settlement of the middle course of the Montsant River. We present the results obtained with respect to the lithic industries, palaeoecology, palaeeconomy, radiocarbon dates, and the latest discovery, an item of mobiliary art. These make it clear that the site belongs to the final Upper Palaeolithic, with specific features that partly distinguish it from the classic Magdalenian. [spa] En este trabajo ofrecemos, por primera vez, los resultados obtenidos hasta el momento en las excavaciones en L'Hort de la Boquera, situado en Margalef de Montsant (Tarragona). El yacimiento forma parte del proyecto de investigación que llevamos a cabo sobre el poblamiento prehistórico del curso medio del río Montsant desde 1979. Los avances se centran en el estudio industrial, de paleoecología, de paleoeconomía, en las dataciones radiocarbónicas y, lo más novedoso, en el del arte mueble, así como en su adscripción a un Paleolítico superior final cuyas características particulares le diferencian del Magdaleniense clásico

Seminari d'Estudis i Recerques Prehistòriques (SERP). Núcleo de cohesión en formación e investigación en Prehistoria de la Universidad de Barcelona desde 1987

El artículo es un resumen amplio de todas las actividades científicas y académicas llevadas a cabo por el SERP (Seminari d'Estudis i Recerques Prehistòriques) desde su fundación en 1987 por parte del Dr. Fullola. Abarca desde programas de excavaciones a proyectos internacionales pasando por temas de Patrimonio arqueológico o de historiografía, entre muchos otros. Además del resumen de dichas actividades, se añade también una completa lista de publicaciones, la gran mayoría en revistas de impacto nacional e internacional. Se incide especialmente en siete líneas básicas de trabajo dentro del grupo, la arqueopetrología, la arqueozoología, el arte prehistórico, la geoarqueología, la paleobotánica, la tecnología, el patrimonio y los estudios territoriales. También se repasan todos y cada uno de los yacimientos objeto de excavación por parte del SERP en estos últimos tres decenios

Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry

Background: The effectiveness of the switch to another anti-tumor necrosis factor (anti-TNF) agent is not known. The aim of this study was to analyze the effectiveness and safety of treatment with a second and third anti-TNF drug after intolerance to or failure of a previous anti-TNF agent in inflammatory bowel disease (IBD) patients. Methods: We included patients diagnosed with IBD from the ENEIDA registry who received another anti-TNF after intolerance to or failure of a prior anti-TNF agent. Results: A total of 1122 patients were included. In the short term, remission was achieved in 55% of the patients with the second anti-TNF. The incidence of loss of response was 19% per patient-year with the second anti-TNF. Combination therapy (hazard ratio [HR], 2.4; 95% confidence interval [CI], 1.8-3; P < 0.0001) and ulcerative colitis vs Crohn's disease (HR, 1.6; 95% CI, 1.1-2.1; P = 0.005) were associated with a higher probability of loss of response. Fifteen percent of the patients had adverse events, and 10% had to discontinue the second anti-TNF. Of the 71 patients who received a third anti-TNF, 55% achieved remission. The incidence of loss of response was 22% per patient-year with a third anti-TNF. Adverse events occurred in 7 patients (11%), but only 1 stopped the drug. Conclusions: Approximately half of the patients who received a second anti-TNF achieved remission; nevertheless, a significant proportion of them subsequently lost response. Combination therapy and type of IBD were associated with loss of response. Remission was achieved in almost 50% of patients who received a third anti-TNF; nevertheless, a significant proportion of them subsequently lost response

Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn’s Disease Patients: The SUSTAIN Study

Background Large real-world-evidence studies are required to confirm the durability of response, effectiveness, and safety of ustekinumab in Crohn’s disease (CD) patients in real-world clinical practice. Methods A retrospective, multicentre study was conducted in Spain in patients with active CD who had received ≥1 intravenous dose of ustekinumab for ≥6 months. Primary outcome was ustekinumab retention rate; secondary outcomes were to identify predictive factors for drug retention, short-term remission (week 16), loss of response and predictive factors for short-term efficacy and loss of response, and ustekinumab safety. Results A total of 463 patients were included. Mean baseline Harvey-Bradshaw Index was 8.4. A total of 447 (96.5%) patients had received prior biologic therapy, 141 (30.5%) of whom had received ≥3 agents. In addition, 35.2% received concomitant immunosuppressants, and 47.1% had ≥1 abdominal surgery. At week 16, 56% had remission, 70% had response, and 26.1% required dose escalation or intensification; of these, 24.8% did not subsequently reduce dose. After a median follow-up of 15 months, 356 (77%) patients continued treatment. The incidence rate of ustekinumab discontinuation was 18% per patient-year of follow-up. Previous intestinal surgery and concomitant steroid treatment were associated with higher risk of ustekinumab discontinuation, while a maintenance schedule every 12 weeks had a lower risk; neither concomitant immunosuppressants nor the number of previous biologics were associated with ustekinumab discontinuation risk. Fifty adverse events were reported in 39 (8.4%) patients; 4 of them were severe (2 infections, 1 malignancy, and 1 fever). Conclusions Ustekinumab is effective and safe as short- and long-term treatment in a refractory cohort of CD patients in real-world clinical practice

Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension

To assess severity markers and outcomes of patients with systemic sclerosis (SSc) with or without pulmonary arterial hypertension (PAH-SSc/non-PAH-SSc), and the impact of interstitial lung disease (ILD) on PAH-SSc. Non-PAH-SSc patients from the Spanish SSc registry and PAH-SSc patients from the Spanish PAH registry were included. A total of 364 PAH-SSc and 1589 non-PAH-SSc patients were included. PAH-SSc patients had worse NYHA-functional class (NYHA-FC), worse forced vital capacity (FVC) (81.2 ± 20.6% vs 93.6 ± 20.6%, P &lt; 0.001), worse tricuspid annular plane systolic excursion (TAPSE) (17.4 ± 5.2 mm vs 19.9 ± 6.7 mm, P &lt; 0.001), higher incidence of pericardial effusion (30% vs 5.2%, P &lt; 0.001) and similar prevalence of ILD (41.8% vs. 44.9%). In individuals with PAH-SSc, ILD was associated with worse hemodynamics and pulmonary function tests (PFT). Up-front combination therapy was used in 59.8% and 61.7% of patients with and without ILD, respectively. Five-year transplant-free survival rate was 41.1% in PAH-SSc patients and 93.9% in non-PAH-SSc patients (P &lt; 0.001). Global survival of PAH-SSc patients was not affected by ILD regardless its severity. The multivariate survival analysis in PAH-SSc patients confirmed age at diagnosis, worse NYHA-FC, increased PVR, reduced DLCO, and lower management with up-front combination therapy as major risk factors. In conclusion, in PAH-SSc cohort risk of death was greatly increased by clinical, PFT, and hemodynamic factors, whereas it was decreased by up-front combination therapy. Concomitant ILD worsened hemodynamics and PFT in PAH-SSc but not survival regardless of FVC impairment